VK 2809

Drug Profile

VK 2809

Alternative Names: MB-07811; VK2809

Latest Information Update: 20 Feb 2017

Price : $50

At a glance

  • Originator Metabasis Therapeutics
  • Developer University of Amsterdam; Viking Therapeutics
  • Class Antihyperlipidaemics; Obesity therapies; Organophosphorus compounds; Small molecules
  • Mechanism of Action Thyroid hormone receptor beta agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hypercholesterolaemia; Non-alcoholic fatty liver disease
  • Preclinical Adrenoleucodystrophy; Glycogen storage disease type I

Most Recent Events

  • 14 Feb 2017 Viking Therapeutics and PoC Capital enter into agreement for VK 2809 in Glycogen Storage Disease Ia
  • 14 Feb 2017 Preclinical trials in Glycogen storage disease type I in USA
  • 14 Feb 2017 Viking Therapeutics plans to file IND for Glycogen storage disease type Ia in 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top